LOGO
LOGO

Economy And The Numbers

Klothos' KLTO-202 Gets Orphan Drug Designation, NRIX Advances Lead Asset, PROK To Meet With FDA

By RTTNews Staff Writer   ✉  | Published:  | Google News Follow Us  | Join Us
rttnewslogo20mar2024

Here's why these stocks are up in premarket trading today.

Klotho Neurosciences Inc.'s (KLTO) novel secreted-Klotho (s-KL) promoter, gene, and delivery system (KLTO-202, or s-KL-AAV.myo) has been granted Orphan Drug Designation by the FDA for the treatment of Amyotrophic Lateral Sclerosis. The company is pioneering the development of novel, disease-modifying cell and gene therapies using a patented, secreted form of the anti-aging Klotho gene (s-KL) to transform the treatment of neurodegenerative and age-related disorders such as ALS, Alzheimer's, and Parkinson's disease. Shares are up 24% at $1.70.

Subscribe to continue reading the article.
This article is available exclusively to RTT Biotech Investor and Intelligent Investor subscribers. Subscribe with a RTTNews subscription.
Start Free Trial
FREE 7-Day Trial - No Payment Required
Already subscribed? Sign in

For comments and feedback contact: editorial@rttnews.com

Economic News

What parts of the world are seeing the best (and worst) economic performances lately? Click here to check out our Econ Scorecard and find out! See up-to-the-moment rankings for the best and worst performers in GDP, unemployment rate, inflation and much more.

Global Economics Weekly Update - Aug 31 – Sep 04, 2026

September 04, 2026 15:08 ET
The job report and foreign trade data were the main economic news from the U.S. in the first week of September. Elsewhere in North America, the Canadian central bank announced its latest policy decision. Inflation data from Eurozone was the highlight in Europe. The latest interest rate decision by the Reserve Bank of New Zealand drew attention in Asia.